Allspring Global Investments Holdings LLC Has $81,000 Stock Holdings in Evolus, Inc. (NASDAQ:EOLS)

Allspring Global Investments Holdings LLC trimmed its stake in Evolus, Inc. (NASDAQ:EOLS) by 37.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,733 shares of the company’s stock after selling 4,612 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Evolus were worth $81,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. grew its holdings in Evolus by 353.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,614 shares of the company’s stock worth $70,000 after purchasing an additional 5,155 shares during the period. Teza Capital Management LLC acquired a new position in shares of Evolus during the 3rd quarter worth approximately $136,000. Kestra Advisory Services LLC increased its holdings in shares of Evolus by 18.5% during the 3rd quarter. Kestra Advisory Services LLC now owns 16,356 shares of the company’s stock worth $149,000 after acquiring an additional 2,550 shares during the last quarter. SG Americas Securities LLC bought a new stake in Evolus in the 3rd quarter valued at $171,000. Finally, Barclays PLC lifted its holdings in Evolus by 24.5% during the 3rd quarter. Barclays PLC now owns 19,794 shares of the company’s stock valued at $181,000 after purchasing an additional 3,889 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Insider Buying and Selling at Evolus

In other news, insider Rui Avelar sold 27,603 shares of the company’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total transaction of $384,233.76. Following the completion of the transaction, the insider now directly owns 372,288 shares in the company, valued at $5,182,248.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider David Moatazedi sold 6,236 shares of the stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $13.86, for a total value of $86,430.96. Following the completion of the sale, the insider now owns 689,614 shares of the company’s stock, valued at $9,558,050.04. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Rui Avelar sold 27,603 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total transaction of $384,233.76. Following the sale, the insider now directly owns 372,288 shares of the company’s stock, valued at approximately $5,182,248.96. The disclosure for this sale can be found here. Insiders have sold a total of 49,038 shares of company stock worth $674,232 over the last 90 days. Insiders own 5.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on EOLS. HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Evolus in a research note on Friday, March 1st. Barclays upgraded Evolus from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $10.00 to $16.00 in a research note on Monday, January 29th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Evolus in a research report on Wednesday, April 10th.

Evolus Price Performance

Shares of NASDAQ:EOLS opened at $11.71 on Tuesday. The company’s 50 day simple moving average is $13.39 and its 200 day simple moving average is $11.29. Evolus, Inc. has a 1 year low of $7.07 and a 1 year high of $15.43. The stock has a market capitalization of $678.48 million, a price-to-earnings ratio of -10.49 and a beta of 1.45.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The firm had revenue of $61.00 million during the quarter, compared to the consensus estimate of $61.14 million. As a group, analysts anticipate that Evolus, Inc. will post -0.51 EPS for the current fiscal year.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.